[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100597300":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":41,"centralContacts":47,"locations":57,"responsibleParty":75,"collaborators":77,"id":81,"slug":51,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":51,"eligibilityCriteria":86,"healthyVolunteers":82,"sex":87,"minAge":88,"maxAge":51,"enrollmentInfo":89,"targetDuration":51,"studyType":92,"phases":93,"briefSummary":95,"conditions":96,"keywords":98,"overallStatus":102,"whyStopped":51,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":112},{"fullName":5,"class":6},"The University of Texas Health Science Center at San Antonio","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Experimental study drug for T1D","EXPERIMENTAL","Dapagliflozin (10 mg\u002Fday) + Pioglitazone (15 mg\u002Fday for 2 weeks, then 30 mg\u002Fday for 14 weeks)",[13,14],"Drug: Dapagliflozin 10mg Tab","Drug: Pioglitazone 15 MG and 30mg",{"label":16,"type":17,"description":18,"interventionNames":19},"Placebo Group for T1D","PLACEBO_COMPARATOR","Dapagliflozin (10 mg\u002Fday) + Placebo (for 16 weeks)",[13,20],"Other: Placebo",[22,29,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":27},"DRUG","Dapagliflozin 10mg Tab","Dapagliflozin (10 mg\u002Fday)",[9,16],[28],"Farxiga",{"type":23,"name":30,"description":31,"armGroupLabels":32,"otherNames":33},"Pioglitazone 15 MG and 30mg","Pioglitazone (15 mg\u002Fday for 2 weeks, then 30 mg\u002Fday for 14 weeks)",[9],[34],"Actos",{"type":6,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"Placebo","Inert placebo for Pioglitazone",[16],[40],"Inert substance",[42,45],{"name":43,"affiliation":5,"role":44},"Muhammad Abdul-Ghani, MD","PRINCIPAL_INVESTIGATOR",{"name":46,"affiliation":5,"role":44},"Ralph DeFronzo, MD",[48,53],{"name":46,"role":49,"phone":50,"phoneExt":51,"email":52},"CONTACT","210 567 6691",null,"defronzo@uthscsa.edu",{"name":54,"role":49,"phone":55,"phoneExt":51,"email":56},"Aurora Merovci, MD, MPH","210 358 7409","merovci@uthscsa.edu",[58],{"facility":59,"status":51,"city":60,"state":61,"zip":62,"country":63,"cosmosGeoPoint":64,"geoPoint":69,"contacts":70},"Texas Diabetes Institute","San Antonio","Texas","78229-3900","United States",{"type":65,"coordinates":66},"Point",[67,68],-98.49363,29.42412,{"lat":68,"lon":67},[71,74],{"name":72,"role":49,"phone":73,"phoneExt":51,"email":52},"Ralph Defronzo, MD","210-567-6691",{"name":54,"role":49,"phone":55,"phoneExt":51,"email":56},{"type":76,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR",[78],{"name":79,"class":80},"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","NIH","100597300",false,"NCT07056699","SGLT2i, Pioglitazone, and Ketone Production in T1D","Protocol V: San Antonio Site Sub Study: Can Pioglitazone Block SGLT2 Inhibitor-induced Stimulation of Lipolysis, Ketone Production and Liver Glucose Production in Type I Diabetic Patients","Inclusion Criteria:\n\n1. Age \\>18 years\n2. T1DM\n3. Other than diabetes, subjects must be in good general health as determined by physical exam, medical history, Chem 20, CBC, TSH, urinalysis, and EKG.\n4. Fasting C-peptide concentration \\\u003C0.7 ng\u002Fml\n5. Poor glycemic control (HbA1c=7.0-11.0%)\n6. Treatment with multiple daily insulin injections (basal plus prandial) or insulin pump\n7. Total daily insulin dose ≥0.6 U\u002Fkg per day\n8. Stable insulin dose (±4 units) in the preceding three months.\n9. eGFR≥60 ml\u002Fmin\n10. Weight stable over the preceding 3 months (± 3 pounds) and who do not participate in an excessively heavy exercise program\n\nExclusion Criteria:\n\n1. T2DM\n2. Daily insulin dose \\\u003C0.6 U\u002Fkg per day\n3. Fasting C-peptide \\>0.7 ng\u002Fml\n4. HbA1c \\\u003C7.0% or \\>11.0%\n5. eGFR\\\u003C60 ml\u002Fmin\n6. Hematuria in urine analysis\n7. Pregnancy, lactating, positive pregnancy test or planning to become pregnant in the following year. Women of child-bearing potential will be requested to use at least two barrier methods before being enrolled in the study.\n8. Major organ system disease which includes: (i) malignancy or history of malignancy including bladder cancer; (ii) Congestive heart failure or history of coronary heart disease or any other cardiac disease; (iii) chronic liver disease or LFT \\>3 times the upper normal level; (iv) History of alcohol or drug abuse; (v) History of chronic lung disease (e.g., COPD, asthma); (vi) history of rheumatic disease; (vii) History of chronic pancreatitis or pancreatic surgery; (viii) History of CVA or TIA (ix) Planned surgery during the study; (x) history of HIV infection or other immune compromised disease; and history of organ transplantation; (xi) patients who take medications, other than insulin, known to affect glucose metabolism, e.g., prednisone.\n9. Evidence of proliferative diabetic retinopathy\n10. Patients enrolled in a heavy exercise program\n11. Patients on ketogenic diet\n12. History of hospitalization for DKA, hypoglycemia or uncontrolled hyperglycemia in the preceding 6 month.\n13. Presence of symptoms of poor glycemic control, e.g. polydipsia or polyurea\n14. History of hypersensitivity to dapagliflozin or pioglitazone","ALL","18 Years",{"count":90,"type":91},24,"ESTIMATED","INTERVENTIONAL",[94],"PHASE3","Participants are being asked to be in a research study. Scientists do research to answer important questions which might help change or improve treatment of participants disease in the future.\n\nIn patients with Type 1 Diabetes (T1D), Dapagliflozin a Selective Glucose Transporter 2 Inhibitor (SGLT2i) is known to increase production of glucose in the liver, increase breakdown of fats (lipolysis), and increase production of ketones (ketogenesis). Ketones are chemicals produced by the liver when the body breaks down fat for energy instead of glucose. When the level of ketones in the body becomes too high, a condition called ketoacidosis develops. In this study, the study team will investigate whether adding pioglitazone (a medication commonly used to treat type 2 diabetes), can reduce the Dapagliflozin - induced liver glucose production, fat break down (lipolysis) and ketone body production (ketogenesis) in patients with Type 1 Diabetes (T1D).",[97],"Type1diabetes",[99,100,101],"Selective Glucose Cotransporter 2 inhibitors (SGLT2i)","Dapagliflozin","Pioglitazone","NOT_YET_RECRUITING","2026-05-12",{"date":105,"type":106},"2026-05-14","ACTUAL",{"date":108,"type":91},"2026-07-01",{"date":110,"type":91},"2027-06-30",{"name":5,"class":6},1]